Back to top
more

Quipt Home Medical (QIPT)

(Real Time Quote from BATS)

$3.50 USD

3.50
6,880

+0.02 (0.58%)

Updated Apr 19, 2024 09:49 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Quipt Home Medical Corp. (QIPT) Reports Q1 Loss, Tops Revenue Estimates

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 66.67% and 3.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quipt Home Medical Corp. (QIPT) Expected to Beat Earnings Estimates: Should You Buy?

Quipt Home Medical Corp. (QIPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts See a 100% Upside in Quipt Home Medical Corp. (QIPT): Can the Stock Really Move This High?

The consensus price target hints at a 100% upside potential for Quipt Home Medical Corp. (QIPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Quipt Home Medical Corp. (QIPT) Reports Q4 Loss, Misses Revenue Estimates

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of -250% and 1.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q1 Loss, Misses Revenue Estimates

Asensus Surgical (ASXC) delivered earnings and revenue surprises of -28.57% and 18.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Quanterix Corporation (QTRX) Soars 33.7%: Is Further Upside Left in the Stock?

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Envista (NVST) Q1 Earnings and Revenues Miss Estimates

Envista (NVST) delivered earnings and revenue surprises of -7.32% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Quipt Home Medical Corp. (QIPT) to Report Q1 Results: Wall Street Expects Earnings Growth

Quipt Home Medical Corp. (QIPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quipt Home Medical Corp. (QIPT) Beats Q4 Earnings Estimates

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 25% and 1.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Quipt Home Medical Corp. (QIPT) Reports Break-Even Earnings for Q3

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of -100% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates

Veru Inc. (VERU) delivered earnings and revenue surprises of -55.56% and 42.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of 9.43% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates

Cerus (CERS) delivered earnings and revenue surprises of 16.67% and 2.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Quanterix Corporation (QTRX): Can Its 5.1% Jump Turn into More Strength?

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Quipt Home Medical Corp. (QIPT) Tops Q2 Earnings Estimates

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 366.67% and 4.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Quipt (QIPT) Ahead of Earnings?

Quipt (QIPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates

OraSure (OSUR) delivered earnings and revenue surprises of -100% and 4.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Quipt Home Medical Corp. (QIPT) Reports Next Week: Wall Street Expects Earnings Growth

Quipt Home Medical Corp. (QIPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clover Health (CLOV) to Report Q1 Earnings: What's in Store?

Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.

Insulet (PODD) Tops Q1 Earnings and Revenue Estimates

Insulet (PODD) delivered earnings and revenue surprises of 73.91% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Quipt (QIPT) Ahead of Earnings?

Quipt (QIPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

QIPT vs. BSX: Which Stock Should Value Investors Buy Now?

QIPT vs. BSX: Which Stock Is the Better Value Option?